Clinical Trial Update: Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II) [Phase 3]

View source ↗

Summary

Phase 3 trial update for pexelizumab in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass (PRIMO-CABG II).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Pexelizumab (pexelizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Coronary Artery Disease | Phase 3 | Status: COMPLETED